Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits
Received 12 March 2018
Accepted for publication 10 April 2018
Published 3 July 2018 Volume 2018:12 Pages 1977—1983
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Qiongyu Guo
Tijana Drobnjak,1 Hamutal Meiri,2,3 Maurizio Mandalá,4 Berthold Huppertz,5 Sveinbjörn Gizurarson1
1Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland; 2Hy Laboratories, Rehovot, Israel; 3TeleMarpe Ltd., Tel Aviv, Israel; 4Department of Biology, Ecology and Earth Sciences, University of Calabria, Rende, Italy; 5Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria
Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia.
Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model.
Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p<0.01). PP13 elimination half-life was also found to be different between the groups (p<0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%.
Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.
Keywords: PP13, ELISA, PK, eNOS, prostaglandin, preeclampsia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]